Atlas Trials

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Clinical trial NCT03432741 · TERMINATED

Trial details

NCT number
NCT03432741
Sponsor
Mayo Clinic
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Breast AdenocarcinomaMetastatic Breast CarcinomaRecurrent Breast CarcinomaRecurrent Hodgkin LymphomaRecurrent Mycosis FungoidesRecurrent Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Breast CarcinomaRefractory Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Nodal Marginal Zone LymphomaRefractory Non-Hodgkin Lymphoma
Start date
2018-03-27
Primary completion
2022-08-26
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.